Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells

Oncotarget

Volumn 6, Issue 17, 2015, Pages 15321-15331

  Bansal, Nitu ^a   Mishra, Prasun J ^b   Stein, Mark ^a   DiPaola, Robert S ^a   Bertino, Joseph R ^a  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b GENENTECH INC   (United States)

Author keywords

Axl and drug resistance; Axl receptor tyrosine kinase; Metformin; Prostate cancer

Indexed keywords

ADENYLATE KINASE; ANTINEOPLASTIC AGENT; AXL RECEPTOR TYROSINE KINASE; CCND1 PROTEIN, HUMAN; CYCLIN D1; DOCETAXEL; FUSED ALICYCLIC AROMATIC COMPOUND; METFORMIN; ONCOPROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; R428 COMPOUND; TAXOID; TRIAZOLE DERIVATIVE;

ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATIC NEOPLASMS; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION;

ADENYLATE KINASE; ANTINEOPLASTIC AGENTS; BENZOCYCLOHEPTENES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; METFORMIN; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; TAXOIDS; TRIAZOLES; UP-REGULATION;

EID: 84934278966     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4148     Document Type: Article

References (41)

1. Aljada A and Mousa SA. Metformin and neoplasia: implications and indications. Pharmacology & therapeutics. 2012; 133:108-115.
2. Bensimon L, Yin H, Suissa S, Pollak MN and Azoulay L. The use of metformin in patients with prostate cancer and the risk of death. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2014; 23:2111-2118.
3. Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC and Fleshner N. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013; 31:3069-3075.
4. Morales DR and Morris AD. Metformin in Cancer Treatment and Prevention. Annual review of medicine. 2014.
5. Andujar-Plata P, Pi-Sunyer X and Laferrere B. Metformin effects revisited. Diabetes research and clinical practice. 2012; 95:1-9.
6. Yoshida T, Okuno A, Tanaka J, Takahashi K, Nakashima R, Kanda S, Ogawa J, Hagisawa Y and Fujiwara T. Metformin primarily decreases plasma glucose not by gluconeogenesis suppression but by activating glucose utilization in a non-obese type 2 diabetes Goto-Kakizaki rats. European journal of pharmacology. 2009; 623:141-147.
7. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. The Journal of clinical investigation. 2010; 120:2355-2369.
8. Rosilio C, Ben-Sahra I, Bost F and Peyron JF. Metformin: A metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer letters. 2014.
9. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27:3576-3586.
10. Hidai C, Zupancic T, Penta K, Mikhail A, Kawana M, Quertermous EE, Aoka Y, Fukagawa M, Matsui Y, Platika D, Auerbach R, Hogan BL, Snodgrass R and Quertermous T. Cloning and characterization of developmental endothelial locus-1: an embryonic endothelial cell protein that binds the alphavbeta3 integrin receptor. Genes & development. 1998; 12:21-33.
11. Sun JC, Liang XT, Pan K, Wang H, Zhao JJ, Li JJ, Ma HQ, Chen YB and Xia JC. High expression level of EDIL3 in HCC predicts poor prognosis of HCC patients. World journal of gastroenterology: WJG. 2010; 16:4611-4615.
12. Zou X, Qiao H, Jiang X, Dong X, Jiang H and Sun X. Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. Journal of biomedical science. 2009; 16:33.
13. Roskoski R, Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacological research: the official journal of the Italian Pharmacological Society. 2014; 79:34-74.
14. Korshunov VA. Axl-dependent signalling: a clinical update. Clinical science. 2012; 122:361-368.
15. Dufies M, Jacquel A, Belhacene N, Robert G, Cluzeau T, Luciano F, Cassuto JP, Raynaud S and Auberger P. Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. Oncotarget. 2011; 2:874-885.
16. Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature genetics. 2012; 44:852-860.
17. Postel-Vinay S and Ashworth A. AXL and acquired resistance to EGFR inhibitors. Nature genetics. 2012; 44:835-836.
18. Costa M, Bellosta P and Basilico C. Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo. Journal of cellular physiology. 1996; 168:737-744.
19. Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, et al. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Cancer research. 2010; 70:1544-1554.
20. Asiedu MK, Beauchamp-Perez FD, Ingle JN, Behrens MD, Radisky DC and Knutson KL. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells. Oncogene. 2014; 33:1316-1324.
21. Ivaska J. Vimentin: Central hub in EMT induction? Small GTPases. 2011; 2:51-53.
22. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB and Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011; 30:1436-1448.
23. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO and Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes care. 2010; 33:322-326.
24. Bowker SL, Majumdar SR, Veugelers P and Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin: Response to Farooki and Schneider. Diabetes care. 2006; 29:1990-1991.
25. Bost F, Sahra IB, Le Marchand-Brustel Y and Tanti JF. Metformin and cancer therapy. Current opinion in oncology. 2012; 24:103-108.
26. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, Deckert M, Auberger P, Tanti JF and Bost F. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer research. 2010; 70:2465-2475.
27. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B and Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer research. 2007; 67:6745-6752.
28. Giles KM, Kalinowski FC, Candy PA, Epis MR, Zhang PM, Redfern AD, Stuart LM, Goodall GJ and Leedman PJ. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther. 2013; 12:2541-2558.
29. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM and Chuang SE. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer letters. 2008; 268:314-324.
30. Ji W, Choi CM, Rho JK, Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, Kim SW, Lee DH and Lee JC. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013; 13:606.
31. Kurokawa M, Ise N, Omi K, Goishi K and Higashiyama S. Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes. Cancer Sci. 2013; 104:904-911.
32. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ and Chuang SE. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res. 2007; 67:3878-3887.
33. Meyer AS, Miller MA, Gertler FB and Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal. 2013; 6:ra66.
34. Neel DS and Bivona TG. Secrets of drug resistance in NSCLC exposed by new molecular definition of EMT. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19:3-5.
35. Zhao Y, Sun X, Jiang L, Yang F, Zhang Z and Jia L. Differential expression of Axl and correlation with invasion and multidrug resistance in cancer cells. Cancer investigation. 2012; 30:287-294.
36. Goruppi S, Ruaro E, Varnum B and Schneider C. Gas6-mediated survival in NIH3T3 cells activates stress signalling cascade and is independent of Ras. Oncogene. 1999; 18:4224-4236.
37. Bellosta P, Costa M, Lin DA and Basilico C. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Molecular and cellular biology. 1995; 15:614-625.
38. Burchert A, Attar EC, McCloskey P, Fridell YW and Liu ET. Determinants for transformation induced by the Axl receptor tyrosine kinase. Oncogene. 1998; 16:3177-3187.
39. Konishi A, Aizawa T, Mohan A, Korshunov VA and Berk BC. Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells. The Journal of biological chemistry. 2004; 279:28766-28770.
40. Vaughan CA, Singh S, Windle B, Yeudall WA, Frum R, Grossman SR, Deb SP and Deb S. Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl. Genes & cancer. 2012; 3:491-502.
41. Chou T. Drug combination studies and their synergy: quantification using the Chou-Talalay method. Cancer Research 2010; 70:440-446.